0 59

Cited 0 times in

Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study)

Authors
 Sung Yong Cho  ;  Seong Jin Jeong  ;  Sangchul Lee  ;  Janghwan Kim  ;  Seong Ho Lee  ;  Min Soo Choo  ;  Seung-June Oh 
Citation
 NEUROUROLOGY AND URODYNAMICS, Vol.40(1) : 286-294, 2021-01 
Journal Title
NEUROUROLOGY AND URODYNAMICS
ISSN
 0733-2467 
Issue Date
2021-01
MeSH
Acetanilides / pharmacology ; Acetanilides / therapeutic use* ; Aged ; Double-Blind Method ; Female ; Humans ; Male ; Parkinson Disease / complications* ; Surveys and Questionnaires ; Thiazoles / pharmacology ; Thiazoles / therapeutic use* ; Treatment Outcome ; Urinary Bladder, Overactive / drug therapy* ; Urological Agents / pharmacology ; Urological Agents / therapeutic use*
Keywords
Parkinson disease ; Parkinsonian disorders ; mirabegron ; overactive ; patient satisfaction ; urinary bladder
Abstract
Aims: This study aimed to investigate the efficacy and safety of mirabegron for Parkinsonism patients with overactive bladder (OAB) symptoms in a randomized, placebo-controlled, multicenter study.

Materials and methods: Inclusion criteria are Parkinsonism with OAB symptoms for 4 weeks or more, OAB symptom score (OABSS) questionnaire scores greater than 2, and OABSS urgency question scores greater than 1. After a 2-week wash-out period, the patients were randomized into placebo and mirabegron groups at visit 2. Visit 3 was performed after 4 weeks of medication. Mirabegron was prescribed to the two groups for the rest of the study period at visit 4.

Result: The mean age was 68.1 ± 8.1 years and 72 males and 64 females were included. A total of 136 patients were screened, 117 patients were randomized, and 25 patients dropped out. The OABSS scores were significantly different between the two groups at Weeks 4 and 8. The OABSS scores became the same in the two groups at Week 12 (visit 5). The postvoid residual urine volume showed a mild increase to 64 ml in the mirabegron group compared to the placebo group at visit 4. Adverse events occurred in 27 patients (23.1%). The degree was mild in 26 cases (78.8%), moderate in five (15.2%), and severe in two (6.1%). Only 13 cases (39.4%) showed medication-related adverse events. Acute urinary retention occurred in a single case. The treatment satisfaction questionnaires showed no significant differences between the two groups.

Conclusion: Mirabegron was effective in treating OAB symptoms in patients with Parkinsonism with acceptable adverse events.
Full Text
https://onlinelibrary.wiley.com/doi/10.1002/nau.24552
DOI
10.1002/nau.24552
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jang Hwan(김장환) ORCID logo https://orcid.org/0000-0002-9056-7072
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/187168
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links